Frontera. The APEX in Gene Therapy Development.

Frontera is a leading clinical-stage biotechnology company that seeks to develop the best gene therapy medicines to improve the lives of patients across multiple disease areas.

Frontera's APEX Technology & Manufacturing Platform is an innovative adeno-associated virus (AAV) gene expression system. It includes novel and clinically validated AAV vectors, efficient and fully-integrated CMC processes, and access to early clinical data, making it possible to develop novel gene therapy products with quicker speed-to-market and lower cost.

  • World-class execution - leveraging fully integrated teams - across disease biology, gene therapy vector design, translational sciences, in-house GMP manufacturing and clinical research.
  • State-of-the-art GMP facilities with up to 2000L scale.
  • World-class and proven team in gene therapy R&D, having been in leading roles or as founders for some of the most successful and innovative gene therapy and gene editing products and companies.
  • Early access to clinical data made possible by Frontera's unique scientific model.

Pipeline

Product development in gene therapy has historically focused on a limited number of rare monogenic disorders. The possibilities for gene therapy, however, are vastly greater. Frontera is realizing this potential with a pipeline that spans across not only orphan diseases, but also in larger patient markets – including Ophthalmology, Hematology, Neuromuscular and Metabolic Diseases.

pipeline-Final9

World-Class R&D Team

Frontera's elite R&D team is made up of founders and scientific advisors from some of the most successful gene therapy development organizations around the world, bringing together the most advanced thinking in gene therapy, genetics, and biologics manufacturing.

Scientific Advisory Board

Scientific Advisory Board

Philip Reilly, Ph.D.

Scientific Advisory Board

Robert Kotin, Ph.D.

Scientific Advisory Board

Fraser Wright, Ph.D.

Scientific Advisory Board

George Church, Ph.D.

Scientific Advisory Board

Jean Bennett, M.D., Ph.D.

Scientific Advisory Board

Mark Kay, M.D., Ph.D.

Scientific Advisory Board

Xandra Breakefield, Ph.D.

Founders

Yong Dai, Ph.D.

Founder & CEO

Philip Reilly, Ph.D.

Co-Founder & Science Advisory Board Chair

Robert Kotin, Ph.D.

Co-Founder & SAB Member

Xinyan Li, Ph.D.

Co-Founder & President

Board of Directors

Wei Li, Ph.D.

Chairman, Founding Partner of Creacion Ventures

Carl Gordon, Ph.D.

Managing Partner, OrbiMed Advisors

David Wang, M.D., Ph.D.

Partner, OrbiMed Advisors

Ching Zhu, Ph.D.

Founding Partner of Creacion Ventures

Yong Dai, Ph.D.

Founder & CEO

Xinyan Li, Ph.D.

Co-Founder & President

Yanling Cao

Partner, Boyu Capital

Jiang Han

Managing Director, Sequoia Capital China

Management Team

The Frontera leadership team's experience spans from principal roles in global pharmaceutical companies to launching innovative biotech’s. The teams' expertise includes early research and development of gene therapy products and biologics, chemistry, manufacturing and Controls (CMC), clinical trial design and management, business development, registration and commercialization.

Management Team

Yong Dai, Ph.D.

Founder & CEO

Management Team

Xinyan Li, Ph.D.

Co-Founder & President

Management Team

Stephen Lau

Chief Business Officer

Management Team

Dean Falb, Ph.D.

Chief Scientific Officer

Management Team

Baochuan Huang

SVP of Manufacturing

Management Team

Robert Lu, Ph.D.

VP of Technical Operations

Management Team

Allison Jia

VP of Finance

Investors

OrbiMed.svg
CreacionLogo
boyu-capital_owler_20160227_223607_original
Sequoia-Capital-China

Recent News

Frontera Therapeutics Receives Additional IND Clearance for its Lead Program FT-001

September 21, 2022

China CDE accepts Investigational New Drug (IND) application for lead gene therapy product candidate, FT-001, for the treatment of a rare inherited eye disease. BEDFORD, Massachusetts, and SHANGHAI, China September 21, 2022 — Frontera Therapeutics, a global clinical-stage biotechnology company that seeks to develop novel and best-in-class gene therapy medicines to improve the lives of […]

Read More

Frontera Therapeutics Completes $160 Million Series B Financing to Fund Clinical Development and Manufacturing Capabilities

July 19, 2022

FDA clears Investigational New Drug (IND) application for lead gene therapy product candidate, FT-001, for the treatment of a rare inherited eye disease leading to severe visual impairment that may result in blindness. Investors in the $160 million Series B round include Boyu Capital, Sequoia China, and existing investors OrbiMed and Creacion Ventures, who were […]

Read More